All Product News

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Lidocaine Ointment USP, 5%. Aurobindo Pharma’s Lidocaine Ointment, are an AB-rated generic equivalent to the reference listed drug (RLD), Lidocaine Ointment manufactured by Fougera Pharmaceuticals Inc. Lidocaine Ointment are indicated: For production […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tofacitinib Extended-Release Tablets, 11 mg. Aurobindo Pharma’s Tofacitinib Extended-Release Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Xeljanz XR Extended-Release Tablets manufactured by Pfizer Inc. Tofacitinib Extended-Release Tablets […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Oseltamivir Phosphate for Oral Suspension, 6 mg/mL. Aurobindo Pharma’s Oseltamivir Phosphate for Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), Tamiflu® for Oral Suspension manufactured by Hoffmann-La […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Colchicine Capsules, 0.6 mg. Aurobindo Pharma’s Colchicine Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD),Mitigare Capsules manufactured by Hikma International Pharmaceuticals LLC. Colchicine Capsules are indicated for: Prophylaxis […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Haloperidol Tablets USP, 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg and 20 mg. Aurobindo Pharma’s Haloperidol Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Haldol® […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Betamethasone Dipropionate Ointment USP, (Augmented), 0.05%. Aurobindo Pharma’s Betamethasone Dipropionate Ointment, are an AB-rated generic equivalent to the reference listed drug (RLD), Diprolene® Ointment manufactured by Organon LLC. Betamethasone Dipropionate Ointment are […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Desmopressin Acetate Tablets, 0.1 mg and 0.2 mg. Aurobindo Pharma’s Desmopressin Acetate Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), DDAVP Tablets manufactured by Ferring Pharmaceuticals, Inc. Desmopressin […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray. Aurobindo Pharma’s Mometasone Furoate Monohydrate Nasal Spray, are an AB-rated generic equivalent to the reference listed drug (RLD), Nasonex Nasal Spray manufactured by Organon LLC. […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Fingolimod Capsules, 0.5 mg. Aurobindo Pharma’s Fingolimod Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Gilenya Capsules manufactured by Novartis Pharmaceuticals Corporation. Fingolimod Capsules are indicated for: The […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg. Aurobindo Pharma’s Mycophenolic Acid Delayed-Release Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Myfortic Delayed-Release Tablets manufactured by […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Mycophenolate Mofetil Tablets USP, 500 mg. Aurobindo Pharma’s Mycophenolate Mofetil Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Cellcept Tablets manufactured by Roche Palo Alto LLC. Mycophenolate Mofetil […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg. Aurobindo Pharma’s Atorvastatin Calcium Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), LIPITOR® Tablets manufactured […]